Cargando…
Anti-AT1R autoantibodies and prediction of the severity of Covid-19
The stimulation of AT1R (Angiotensin II Receptor Type 1) by Angiotensin II has, in addition to the effects on the renin-angiotensin system, also pro-inflammatory effects through stimulation of ADAM17 and subsequent production of INF-gamma and Interleukin-6. This pro-inflammatory action stimulate the...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577881/ https://www.ncbi.nlm.nih.gov/pubmed/34772541 http://dx.doi.org/10.1016/j.humimm.2021.10.006 |
_version_ | 1784596153596116992 |
---|---|
author | Papola, Franco Biancofiore, Veronica Angeletti, Chiara Grimaldi, Alessandro Carucci, Anna Cecilia Cofini, Vincenza Necozione, Stefano Rosciano, Alessia Marinangeli, Franco Cervelli, Carla |
author_facet | Papola, Franco Biancofiore, Veronica Angeletti, Chiara Grimaldi, Alessandro Carucci, Anna Cecilia Cofini, Vincenza Necozione, Stefano Rosciano, Alessia Marinangeli, Franco Cervelli, Carla |
author_sort | Papola, Franco |
collection | PubMed |
description | The stimulation of AT1R (Angiotensin II Receptor Type 1) by Angiotensin II has, in addition to the effects on the renin-angiotensin system, also pro-inflammatory effects through stimulation of ADAM17 and subsequent production of INF-gamma and Interleukin-6. This pro-inflammatory action stimulate the cytokine storm that characterizes the most severe forms of SARS-CoV-2 infection. We studied the effect of AT1Rab on the AT1R on 74 subjects with SARS-CoV-2 infection with respiratory symptoms requiring hospitalization. We divided the patients into 2 groups: 34 with moderate and 40 with severe symptoms that required ICU admission. Hospitalized subjects showed a 50% reduction in the frequency of AT1Rab compared to healthy reference population. Of the ICU patients, 33/40 (82.5%) were AT1Rab negative and 16/33 of them (48.5%) died. All 7 patients positive for AT1Rab survived. These preliminary data seem to indicate a protective role played by AT1R autoantibodies on inflammatory activation in SARS-CoV-2 infection pathology. |
format | Online Article Text |
id | pubmed-8577881 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85778812021-11-10 Anti-AT1R autoantibodies and prediction of the severity of Covid-19 Papola, Franco Biancofiore, Veronica Angeletti, Chiara Grimaldi, Alessandro Carucci, Anna Cecilia Cofini, Vincenza Necozione, Stefano Rosciano, Alessia Marinangeli, Franco Cervelli, Carla Hum Immunol Short Communication The stimulation of AT1R (Angiotensin II Receptor Type 1) by Angiotensin II has, in addition to the effects on the renin-angiotensin system, also pro-inflammatory effects through stimulation of ADAM17 and subsequent production of INF-gamma and Interleukin-6. This pro-inflammatory action stimulate the cytokine storm that characterizes the most severe forms of SARS-CoV-2 infection. We studied the effect of AT1Rab on the AT1R on 74 subjects with SARS-CoV-2 infection with respiratory symptoms requiring hospitalization. We divided the patients into 2 groups: 34 with moderate and 40 with severe symptoms that required ICU admission. Hospitalized subjects showed a 50% reduction in the frequency of AT1Rab compared to healthy reference population. Of the ICU patients, 33/40 (82.5%) were AT1Rab negative and 16/33 of them (48.5%) died. All 7 patients positive for AT1Rab survived. These preliminary data seem to indicate a protective role played by AT1R autoantibodies on inflammatory activation in SARS-CoV-2 infection pathology. American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. 2022-02 2021-11-10 /pmc/articles/PMC8577881/ /pubmed/34772541 http://dx.doi.org/10.1016/j.humimm.2021.10.006 Text en © 2021 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Communication Papola, Franco Biancofiore, Veronica Angeletti, Chiara Grimaldi, Alessandro Carucci, Anna Cecilia Cofini, Vincenza Necozione, Stefano Rosciano, Alessia Marinangeli, Franco Cervelli, Carla Anti-AT1R autoantibodies and prediction of the severity of Covid-19 |
title | Anti-AT1R autoantibodies and prediction of the severity of Covid-19 |
title_full | Anti-AT1R autoantibodies and prediction of the severity of Covid-19 |
title_fullStr | Anti-AT1R autoantibodies and prediction of the severity of Covid-19 |
title_full_unstemmed | Anti-AT1R autoantibodies and prediction of the severity of Covid-19 |
title_short | Anti-AT1R autoantibodies and prediction of the severity of Covid-19 |
title_sort | anti-at1r autoantibodies and prediction of the severity of covid-19 |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577881/ https://www.ncbi.nlm.nih.gov/pubmed/34772541 http://dx.doi.org/10.1016/j.humimm.2021.10.006 |
work_keys_str_mv | AT papolafranco antiat1rautoantibodiesandpredictionoftheseverityofcovid19 AT biancofioreveronica antiat1rautoantibodiesandpredictionoftheseverityofcovid19 AT angelettichiara antiat1rautoantibodiesandpredictionoftheseverityofcovid19 AT grimaldialessandro antiat1rautoantibodiesandpredictionoftheseverityofcovid19 AT carucciannacecilia antiat1rautoantibodiesandpredictionoftheseverityofcovid19 AT cofinivincenza antiat1rautoantibodiesandpredictionoftheseverityofcovid19 AT necozionestefano antiat1rautoantibodiesandpredictionoftheseverityofcovid19 AT roscianoalessia antiat1rautoantibodiesandpredictionoftheseverityofcovid19 AT marinangelifranco antiat1rautoantibodiesandpredictionoftheseverityofcovid19 AT cervellicarla antiat1rautoantibodiesandpredictionoftheseverityofcovid19 |